An individual transaction involving the transfer to Tillotts Pharma AG of the marketing authorisation for fidaxomicin (Dificlir) in Europe, the Middle East and Africa and certain CIS regions, together with the related technology transfer agreement, with the marketing authorisations to be transferred on a regional basis.